[IO Summit 2022] Quantify Antibody-Dependent Cell Phagocytosis (ADCP): Application of a Robust, Non-Radioactive KILR Cytotoxicity Platform

[IO Summit 2022] Quantify Antibody-Dependent Cell Phagocytosis (ADCP): Application of a Robust, Non-Radioactive KILR Cytotoxicity Platform
Version:
21382

File Name/Number:
IO Summit

Year:
2022

 

Cell-based assays play an important role in determination of mechanism of action (MOA) for therapeutic antibodies, particularly when evaluating their potential for effector functions. Antibody-dependent cellular phagocytosis(ADCP) has gained prominence as an important MOA to evaluate, especially for IND-enabling studies of antibodies with modified Fc regions. ADCP is mediated by a variety of effector cells, namely monocytes, macrophages, dendritic cells, and neutrophils, through multiple FcγRs. While the Fab region of the antibody binds to a specific antigen on the surface of target cells, the Fc region of the antibody binds and activates various Fcγ receptors on effector cells. Activation of specific Fcγ receptors, like FcγRIIa, FcγRI, and FcγRIIIa, leads to activation of a complex pathway that results in phagocytosis and destruction of the target cells in the lysosome of the effector cells.